Shionogi & Co Ltd 2018 Integrated Report
The report presents Shionogi Group's fiscal 2017 performance and its purpose-led strategy as a drug discovery-based pharmaceutical company. The company reported net sales of ¥344.7 billion, launched Xofluza in Japan, and continued work addressing infectious diseases and pain/CNS disorders. Its sustainability coverage includes CSR, antimicrobial-resistance initiatives, EHS management, and a goal to reduce CO2 emissions by 33% from the fiscal 2005 benchmark by fiscal 2020.
Company: Shionogi & Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2018
Type: Integrated Report
Pages: 82
Back to company
Shionogi & Co Ltd
Integrated Report
The report presents Shionogi Group's fiscal 2017 performance and its purpose-led strategy as a drug discovery-based pharmaceutical company. The company reported net sales of ¥344.7 billion, launched Xofluza in Japan, and continued work addressing infectious diseases and pain/CNS disorders. Its sustainability coverage includes CSR, antimicrobial-resistance initiatives, EHS management, and a goal to reduce CO2 emissions by 33% from the fiscal 2005 benchmark by fiscal 2020.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women in Management
Employees